Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

In this Spotlight On Lower-Risk MDS, learn more about:

Updates on risk-stratification & disease classification

Recognizing ESA failure, and when to switch therapy

The latest therapy updates for LR-MDS beyond ESAs

The diagnosis and risk-stratification of patients with MDS has moved forward in recent years
to include the identification of several genomic targets1

Revisions to the ICC and WHO classifications of AML and MDS

Sanam Loghavi, MD
MD Anderson Cancer Center, Houston, TX

Advances in LR-MDS and HR-MDS in 2023 and beyond

Amer Zeidan, MBBS
Yale Cancer Center, New Haven, CT

Potential MDS targets
beyond HMAs

Aditi Shastri, MD
Montefiore Medical Center, Bronx, NY

Diagnosis, risk stratification and treatment of LR-MDS

Leading experts Sanam Loghavi, MD Anderson Cancer Center, Houston, TX, and Rami Komrokji, Moffitt Cancer Center, Tampa, FL, discuss recent advances in the diagnosis, risk stratification and treatment of LR-MDS in this webinar available to view on demand.

Approaching ESA failure in patients with LR-MDS

The current standard of care for patients with transfusion-dependent LR-MDS and symptomatic anemia is ESAs.2 However, responses are limited, with patients at the eventual risk of ESA failure.2

Valeria Santini, MD, University of Florence, Florence, Italy, comments on factors that influence patient responses to ESAs, how to approach ESA failure in patients with lower-LR-MDS, and next steps for these patients.

Latest updates in the treatment of LR-MDS beyond ESAs
Canakinumab with darbepoetin in patients who are ESA-refractory

Jeffrey Lancet, MD
Moffitt Cancer Center, Tampa, FL

Luspatercept trials: COMMANDS, MEDALIST and ELEMENTS-MDS

Amer Zeidan, MBBS
Yale Cancer Center, New Haven, CT

IMerge trial: the disease-modifying potential of imetelstat in LR-MDS

Uwe Platzbecker, MD
University of Leipzig, Leipzig, Germany

See for the latest information on the Phase III COMMANDS and IMerge trials in LR-MDS


  1. Garcia-Manero, G. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98(8):1307–1325.
  2. Brunner, AM, et al. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J 2022;12:166.


ESA, erythropoietin-stimulating agent; ICC, International Consensus Classification; LR, lower risk; MDS, myelodysplastic syndromes; WHO, World Health Organization


This educational activity has received independent medical education support from
Bristol Myers Squibb. This supporter has no influence over the production of the content.